ARTICLE | Clinical News
Exact HCC assay significantly better than SOC
June 5, 2018 8:37 PM UTC
Exact Sciences Corp. (NASDAQ:EXAS) reported data showing that its hepatocellular carcinoma blood test had greater sensitivity and specificity in identifying HCC, especially early stage cancer, vs. the standard of care alpha fetoprotein (AFP) test.
The test is the most advanced in Exact's pipeline behind its marketed Cologuard colorectal cancer screening test...